The Eurasian Intergovernmental Council approved an action plan to increase the level of supply of the EAEU states with strategically important medicines and pharmaceutical substances for medical use, the production of which must be ensured in the EAEU by 2024. The corresponding order was published on the website of the Eurasian Economic Commission.
According to the plan, the EAEU member states have to jointly approve, by the end of 2022, the criteria by which medicines are going to be classified as strategically important. Based on these criteria, a final list will be formed.
By the end of 2024, the EAEU will determine the support measures that will allow full-cycle production of strategically important medicines in the Union, without the need to import pharmaceutical substances.
Moreover, special customs regulation will be introduced for this purpose in the Eurasian Economic Union for pharmaceutical substances that are recognized as strategically important. This gives manufacturers an opportunity to reduce production costs.
A separate item of the plan is the creation of joint production capacities in the EAEU. First of all, this concerns drugs for the prevention of coronavirus infection.
The Eurasian Economic Commission will prepare a report for each item of the plan every year, providing all information on its implementation.
Earlier, Mishustin called for ensuring equal availability of medicines in the EAEU.
